- |||||||||| Olysio (simeprevir) / J&J, Medivir
Biomarker, Clinical, Journal: Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with direct-acting antiviral therapy. (Pubmed Central) - Dec 16, 2021 We sought to analyze the kinetics profiles of serum biomarkers (LuminexTM) in fifty patients with chronic hepatitis C enrolled in a longitudinal investigation carried out before (baseline), during (W2-4 and W8-12 weeks) and post-treatment (W12-24 weeks) with sofosbuvir plus daclatasvir or simeprevir...High ALT (>69U/L), low platelet (≤150,000/mm) and cirrhosis status at baseline were factors related to delayed immune response shift, as well as, in the kinetics of baseline fold changes in serum biomarkers. These findings added novel evidences for the immunological restoration process triggered by DAAs.
- |||||||||| Olysio (simeprevir) / J&J, Medivir
Biomarker, Journal: Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment. (Pubmed Central) - Oct 30, 2021 Presence of diabetes and complications related to liver disease (splenomegaly, portal hypertension, portal hypertensive gastropathy), body mass index ≥30, greater liver fibrosis, receiving simeprevir and higher baseline levels of glucose, aspartate-aminotransferase, alanine-aminotransferase and alkaline-phosphatase, have been identified as predictive factors of non-response (p < 0.05)...The effectiveness and safety of direct-acting antivirals against hepatitis C virus have been maintained in routine clinical practice. Further research on predictive factors of response is required in order to develop more reliable and reproducible predictive models.
- |||||||||| Olysio (simeprevir) / J&J, Medivir
Extranodal Liver, Pancreas and Spleen Diffuse Large B Cell Lymphoma After Successful Treatment for Chronic Hepatitis C Infection Using Direct Acting Antiviral Therapy (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_2604; The relationship for HCV infection and development of lymphomas is well established,but pathophysiology is not well understood.One of the most accepted hypotheses is chronic viral antigen stimulation and genetic mutations to lymphocytes arising from HCV‐induced replication proteins.Physicians need to be aware that DAA therapy is clearly effective for intra- and extrahepatic manifestations of the virus, but these patients are still at risk for malignancy regardless HCV serologic status.Figure: PET-CT SCAN showing in the lower half of the right liver lobe three large foci of increased tracer uptake, the larger lesion located on the anterolateral aspect of segment VIII measuring 4.3cm AP, also shows a soft tissue mass in pancreatic head with caudal extension that measures 3.7cm AP. There is no main pancreatic duct dilation (b), and a small lesion on superior-posterior aspect subcapsular area of the spleen (c).
- |||||||||| Trial completion date, Trial primary completion date: SWITCH-1: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Aug 30, 2021
P2, N=160, Recruiting, There is no main pancreatic duct dilation (b), and a small lesion on superior-posterior aspect subcapsular area of the spleen (c). Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Oct 2020 --> Oct 2022
- |||||||||| Olysio (simeprevir) / J&J, Medivir
Clinical, Journal: Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy. (Pubmed Central) - Aug 20, 2021 In these two cases, previously experienced to peg-interferon plus ribavirin, the sofosbuvir plus simeprevir therapy was effective, without significant side effects, and interrupted the evolution of at least 20 years of both hepatic and renal diseases. These cases join the seven previously described cases that were treated with this DAAs association.
- |||||||||| Olysio (simeprevir) / J&J, Medivir
Clinical, Journal, Real-world evidence: Cost and Effectiveness of the Treatment of Chronic Hepatitis C in Brazil: Real-World Data. (Pubmed Central) - Jul 22, 2021 The costs of the medicines were still deemed too high for the Brazilian reality, however. Therefore the results contribute to support the formulation and review of public policies based on strong evidence and on real-world data for the treatment of hepatitis C.
- |||||||||| imatinib / Generic mfg.
Preclinical, Journal: Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2. (Pubmed Central) - Jun 16, 2021 FDA approved drug molecules were screened by their capabilities of blocking the formation of the key pair of salt bridges, achieved by their positional stabilities in the cavity containing the side chains of K537 and E619 formed in the interface between SD1 and SD2. Simeprevir, imatinib, and naldemedine were identified to possess the desired capability with the most favorable interaction energies.
- |||||||||| Olysio (simeprevir) / J&J, Medivir
Journal: Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. (Pubmed Central) - Jun 3, 2021 Mechanistically, we showed that simeprevir not only inhibits the main protease (M) and unexpectedly the RNA-dependent RNA polymerase (RdRp) but also modulates host immune responses. Our results thus reveal the possible anti-SARS-CoV-2 mechanism of simeprevir and highlight the translational potential of optimizing simeprevir as a therapeutic agent for managing COVID-19 and future outbreaks of CoV.
- |||||||||| Olysio (simeprevir) / J&J, Medivir
Journal: Antivirals virtual screening to SARS-CoV-2 non-structural proteins. (Pubmed Central) - May 6, 2021 Moreover, the results suggest that simeprevir is a strong inhibitor of Mpro (-37.2 kcal mol), which is an interesting finding because Mpro plays an important role in viral replication. In addition to drug-receptor affinity, hot spot residues were characterized to facilitate the design of new drug derivatives with improved biological responses.
- |||||||||| Olysio (simeprevir) / J&J, Medivir
Preclinical, Journal: In vitro susceptibility of human Blastocystis subtypes to simeprevir. (Pubmed Central) - May 4, 2021 Ultra-structurally, SMV induced rupture of Blastocystis cell membrane leading to necrotic death, versus the reported apoptotic death caused by MTZ. In conclusion, 150 µg/ml SMV for 72 h proved its efficacy against ST1, ST2, and ST3 Blastocystis, thus sparing the need for pre-treatment molecular subtyping in developing countries.
- |||||||||| Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: A real-life study of the positive response to DAA-based therapies for hepatitis C in Brazil. (Pubmed Central) - Apr 10, 2021 This study is the first of this magnitude to be held in a Latin-American country with high SVR results, supported by a free-of-charge universal and public health system. The high performance found in this study gives support to the Brazilian public health policy decision of adopting DAA-based therapies as a strategy to eliminate HCV by 2030.
|